GSK’s RSV vaccine meets main goal when co-administered with shingles shot

(Reuters) – British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.

The company said co-administration of the vaccines generated an immune response that was at least on-par with separate administration.

(Reporting by Prerna Bedi in Bengaluru; Editing by Varun H K)